Trump Executive Order Tracker | Akin Public Policy and Lobbying

Regulatory Relief to Promote Domestic Production of Critical Medicines (Trump EO Tracker)

May 5, 2025

Reading Time : 1 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

Within 180 days, the order directs the Secretary of Health and Human Services, through the FDA Commissioner, to review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing.

Within 90 days of the order, the FDA Commissioner is directed to develop and advance improvements to the risk-based inspection regime that ensures routine reviews of overseas manufacturing facilities involved in the supply of United States medicines, funded by increased fees on foreign manufacturing facilities and the FDA Commissioner must publicly disclose the annual number of inspections that the FDA conducts on such foreign facilities.

Within 180 days, the order instructs the Administrator of the Environmental Protection Agency (EPA) to take action to update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review.

Within 180 days of the order, the Secretary of the Army, acting through the Assistant Secretary of the Army for Civil Works, shall review the nationwide permits issued under section 404 of the Clean Water Act of 1972 (33 U.S.C. 1344) and section 10 of the Rivers and Harbors Appropriation Act of 1899 (33 U.S.C. 403) to determine whether an activity-specific nationwide permit is needed to facilitate the efficient permitting of pharmaceutical manufacturing facilities.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

July 13, 2026

Modifies the boundaries of the Bears Ears National Monument by reducing its size from approximately 1.36 million acres to approximately 121,096 acres. 

...

Read More

Trump Executive Order Tracker

July 13, 2026

Reduces the size of the Grand Staircase-Escalante National Monument by modifying its boundaries and removing certain federal lands from monument protection.

...

Read More

Trump Executive Order Tracker

July 13, 2026

Directs federal agencies to expand support for regenerative agriculture and precision farming technologies while promoting research, innovation, and public-private partnerships to improve soil health, strengthen farm resilience, and enhance long-term food security. Prioritizes expedited review of newer agricultural products, research into cumulative chemical exposures in the food supply, and expanded federal investment in regenerative farming practices, while stating that agencies should not exceed existing statutory regulatory authorities.

...

Read More

Trump Executive Order Tracker

June 25, 2026

Directs federal agencies to expand support for regenerative agriculture and precision farming technologies while promoting research, innovation, and public-private partnerships to improve soil health, strengthen farm resilience, and enhance long-term food security. Prioritizes expedited review of newer agricultural products, research into cumulative chemical exposures in the food supply, and expanded federal investment in regenerative farming practices, while stating that agencies should not exceed existing statutory regulatory authorities.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.